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Prognostic Value of Changes
in N-Terminal Pro-Brain Natriuretic Peptide
in Val-HeFT (Valsartan Heart Failure Trial)
Serge Masson, PHD,* Roberto Latini, MD,*† Inder S. Anand, MD, FACC, FRCP, DPHIL (OXON),‡
Simona Barlera, MS,* Laura Angelici, MS,* Tarcisio Vago, BIOLD,§ Gianni Tognoni, MD,
Jay N. Cohn, MD, FACC,¶ for the Val-HeFT Investigators
Milan and Chieti, Italy; Valhalla, New York; and Minneapolis, Minnesota
Objectives This study sought to evaluate the association between changes over time of N-terminal pro-brain natriuretic pep-
tide (NT-proBNP) expressed in different ways and outcome in patients with stable and chronic heart failure (HF).
Background Although previous studies examined the prognostic value of repeated determinations of BNP in HF, there are
only limited data on the clinical utility of serial measurements of the inactive peptide NT-proBNP in a large
population of ambulatory patients with chronic HF with sufficient follow-up time.
Methods The NT-proBNP was measured at randomization and after 4 months in 1,742 patients enrolled in the placebo
arm of Val-HeFT (Valsartan Heart Failure Trial). Changes in NT-proBNP concentrations over 4 months were ex-
pressed as absolute change from baseline, percent relative changes, or categorical changes across a threshold
value and related to subsequent mortality.
Results A single determination of NT-proBNP (area under the curve at 4 months: 0.702, 95% confidence interval
[CI]: 0.669 to 0.735) showed a higher prognostic discrimination than continuous changes of concentrations, ex-
pressed either as absolute (0.592, 95% CI: 0.549 to 0.634) or relative changes (0.602, 95% CI: 0.566 to 0.639).
A Cox proportional hazards model showed that stratification of patients into 4 categories according to NT-
proBNP levels at 2 time points 4 months apart with respect to a threshold concentration provided prognostic
information in patients with chronic HF beyond that of a single determination.
Conclusions Serial determinations of NT-proBNP concentration and classification into few categories of changes according to
threshold levels may be a superior strategy for risk stratification of patients with chronic and stable HF. (J Am
Coll Cardiol 2008;52:997–1003) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.069a
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osingle measurement of a natriuretic peptide at any time
uring the progression of chronic heart failure (HF) provides a
linically useful tool for risk stratification in different clinical
ettings (1,2). Elevation of natriuretic peptides concentration
brain natriuretic peptide [BNP] or N-terminal pro-brain
atriuretic peptide [NT-proBNP]), in particular in patients
ith acutely decompensated HF, predicts adverse outcomes
uch as death or readmission in hospital for HF. Both peptides
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Manuscript received January 10, 2008; revised manuscript received March 18,
008, accepted April 23, 2008.re the strongest prognostic circulating biomarkers, even in the
resence of robust clinical risk factors in HF, such as age, New
ork Heart Association (NYHA) functional class, or ischemic
tiology (3–5). There are, however, fewer reports on the clinical
tility of serial biomarker testing in ambulatory patients
See page 1004
ith chronic HF. In the RESOLVD (Randomized Evaluation
f Strategies for Left Ventricular Dysfunction) pilot study (6),
aseline and 17-week changes in N-terminal pro-atrial natri-
retic peptide were independently associated with death and
F hospitalization in 768 patients with left ventricular (LV)
ystolic dysfunction and HF. In addition, elevation of BNP at
ny time during clinical follow-up predicted an increased risk
f events in 190 ambulatory patients with chronic HF (7).
In Val-HeFT (Valsartan Heart Failure Trial), serial
easurements and changes in BNP concentration over time
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a large population of patients
(4,000) with chronic and
symptomatic HF (3,8). In the
same trial, the amino-terminal
fragment of BNP (NT-proBNP)
showed only subtle differences in
terms of prognostic value when
compared with the active hor-
mone BNP (9). Here, we aimed
at determining whether serial
determinations of NT-proBNP
can also provide useful clinical
information in a large, well-
characterized population of pa-
tients with chronic, stable, and
symptomatic HF with sufficient
follow-up time.
Methods
Study design and patients. The
al-HeFT study was a randomized, placebo-controlled,
ouble-blind, parallel-arm multicenter trial. A total of 5,010
atients with stable, symptomatic HF who were on pre-
cribed HF therapy and had left ventricular ejection fraction
LVEF) 40% and left ventricular diameter in diastole
djusted for body surface area 2.9 cm/m2 were enrolled in
he study (10). To avoid the confounding effect of the
andomized active treatment (valsartan) on the concentra-
ions of NT-proBNP over time, the present analyses were
erformed on patients enrolled in the placebo arm of the
rial who had NT-proBNP measured at study entry and
fter 4 months of follow-up (n  1,742).
easurement of NT-proBNP. Blood samples were col-
ected on potassium-ethylenediaminetetracetic acid at study
ntry and after 4 months for measurement of NT-proBNP
ith an electrochemiluminescence immunoassay on an
lecsys 2010 analyzer (Roche Diagnostics, Rotkreuz, Swit-
erland), as reported (9). The intra-assay coefficient of
ariation was 2.9%, and the interassay coefficient of varia-
ion was 3.6%. The reference value in 377 age-matched
pparently healthy volunteers (mean age 60  4 years, 76%
ale) was a median of 38 pg/ml (range of Q1 to Q3: 20 to
3 pg/ml, 95th percentile  157 pg/ml).
tatistical methods. Outcome was adjudicated by a central
nd point committee. The independent prognostic contri-
ution of baseline and 4-month concentrations of NT-
roBNP (considered log-transformed variables), in addition
o the variables that were clinically relevant and statistically
ignificant, was assessed in incremental Cox proportional
azards models by the likelihood ratio test.
Changes in NT-proBNP concentration from baseline to
months were expressed by 3 different methods: absolute
hange from baseline, percent relative change from baseline,
Abbreviations
and Acronyms
AUC  area under the
receiver-operator
characteristic curve
BNP  brain natriuretic
peptide
CI  confidence interval
cTnT  cardiac troponin T
HF  heart failure
HR  hazard ratio
LV  left ventricular
LVEF  left ventricular
ejection fraction
NT-proBNP  N-terminal
pro-brain natriuretic peptide
NYHA  New York Heart
Association
ROC  receiver-operator
characteristicnd categorical changes. Absolute and percent relative Mhanges from baseline were analyzed by quartiles for subse-
uent mortality. For categorical changes, patients with
T-proBNP measurements available at baseline and 4
onth follow-up were divided into 4 groups, based on
hanges in NT-proBNP concentrations from baseline to 4
onths across a threshold level. This level was calculated as
he concentration of NT-proBNP at baseline that gave the
ighest prognostic accuracy for mortality (product of spec-
ficity and sensitivity) by univariate time-dependent
eceiver-operator characteristic (ROC) curve (1,078 pg/ml,
pecificity 0.619, sensitivity 0.619). We defined 4 categories:
. low¡low (patients with NT-proBNP below the thresh-
old concentration of 1,078 pg/ml at baseline and after 4
months)
. high¡high (patients with NT-proBNP above the
threshold at baseline and after 4 months)
. high¡low (patients with NT-proBNP above the thresh-
old at baseline and below after 4 months)
. low¡high (patients with NT-proBNP below the thresh-
old at baseline and above after 4 months)
Cumulative survival estimates were presented as Kaplan-
eier curves for the 4 categories and compared using the
og-rank test.
The prognostic discrimination of a single determination
baseline or 4 months) or continuous changes over time
absolute or percent) of NT-proBNP concentration was
ssessed by time-dependent univariate ROC curves (11).
his was evaluated by the area under the ROC curve, which
s equivalent to the C-index. Comparisons between the
reas under the ROC curves were performed by pairwise
ethod with the use of U statistics (12). A Cox proportional
azards model was used to compare the risk of death in each
ategory using the low¡low group as a reference category.
aseline or 4-month concentrations of NT-proBNP were
lso included in the model because they were the strongest
redictors of outcome. The model was adjusted for all
ariables that were found to be statistically significant in the
nivariate analysis (age, body mass index, serum creatinine
t baseline, ischemic etiology of HF, NYHA functional
lass, LV ejection fraction and diameter, and prescription of
igoxin and diuretics).
All probability values are 2-tailed at 5% significance level.
nalyses were performed using SAS software, version 9.1.3
SAS Institute Inc., Cary, North Carolina) and the libraries
misc and survivalROC of the R language (13).
esults
aseline characteristics. Table 1 summarizes the clinical
nd demographic features of the patients at baseline. The
opulation was predominantly male (80.6%) with a mean
ge of 63  11 years. Over 37% of patients were in NYHA
unctional classes III and IV; the mean LVEF was 27%.edian (Q1 to Q3) concentrations of NT-proBNP were
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g/ml after 4 months of follow-up (n  1,742).
Two hundred and sixty-seven patients died during a
edian follow-up time of 24.5 months. Patients who died
efore 4 months of follow-up (n 117) were excluded from
he analysis related to changes in NT-proBNP concentra-
ion and subsequent mortality. Baseline NT-proBNP, en-
ered as a continuous log-transformed variable, was the
trongest independent predictor of mortality in a multivari-
te model that included all of the significant clinical risk factors
hazard ratio [HR]: 1.403, 95% confidence interval [CI]: 1.241
o 1.585, chi-square: 29.47, p 0.0001) (Table 2). The other
ignificant variables in this model were (by decreasing order
f chi-square): LV internal diameter, prescription of beta-
lockers, NYHA functional class, and ischemic etiology of
F. Addition of the concentration of NT-proBNP mea-
ured at 4 months in the previous model provided incre-
ental prognostic value as evaluated by the likelihood ratio
est (increment of chi-square by 42, p  0.0001 for 1° of
reedom). In this new model, NT-proBNP at 4 months was
ssociated with a significant risk of all-cause mortality (HR:
aseline Demographic and Clinical Characteristics
Table 1 Baseline Demographic and Clinical Characteristics
n  1,742
Age (yrs), mean SD 63 11
Male, n (%) 1,404 (80.6)
NYHA functional classes III to IV, n (%) 647 (37.1)
Ischemic etiology, n (%) 1,004 (57.6)
LVEF (%), mean SD 27 7
BMI 22 kg/m2, n (%) 174 (10.0)
LVIDd (cm), mean SD 6.93 0.91
Heart rate (beats/min), mean SD 73 11
Sitting SBP (mm Hg), mean SD 125 19
Serum creatinine (mol/l), mean SD 112 26
Serum bilirubin (mol/l), mean SD 11.3 5.9
ACEi, n (%) 1,635 (93.9)
Beta-blockers, n (%) 664 (38.1)
Digoxin, n (%) 1,177 (67.6)
Diuretics, n (%) 1,461 (83.9)
NT-proBNP at entry (pg/ml), median (Q1–Q3) 861 (368–1,803)
NT-proBNP at 4 months (pg/ml), median (Q1–Q3) 783 (327–1,781)
CEi  angiotensin-converting enzyme inhibitor; BMI  body mass index; LVEF  left ventricular
jection fraction; LVIDd  left ventricular internal diameter in diastole; NT-proBNP  N-terminal
ro-brain natriuretic peptide; NYHA  New York Heart Association; SBP  systolic blood pressure;
 quartile.
redictors of All-Cause Mortalityy Multivariable ox Regression Analysis
Table 2 Predictors of All-Cause Mortalityby Multivariable Cox Regression Analysis
Variable HR (95% CI) Chi-Square p Value
Baseline NT-proBNP
(1 increment on log scale)
1.403 (1.241–1.585) 29.47 0.0001
Left ventricular internal
diameter 6.8 cm
1.696 (1.305–2.204) 15.61 0.0001
Prescription of beta-blockers 0.589 (0.444–0.781) 13.52 0.0002
NYHA functional classes III to IV 1.560 (1.216–2.001) 12.21 0.0005
Ischemic etiology of heart failure 1.447 (1.118–1.872) 7.87 0.0050bI  confidence interval; HR  hazard ratio; other abbreviations as in Table 1..993, 95% CI: 1.616 to 2.459, chi-square: 41.43, p 
.0001). When the concentration of NT-proBNP at 4
onths was entered in the model, baseline NT-proBNP
emained a marginal predictor (HR: 0.776, 95% CI: 0.623
o 0.965, chi-square: 5.18, p  0.0228). These models did
ot include other circulating biomarkers, such as BNP.
owever, in a separate multivariate analysis considering
NP instead of NT-proBNP, the strongest predictor for
he risk of death was BNP (for each increment of 50 pg/ml,
R: 1.072, 95% CI: 1.050 to 1.095, chi-square: 43.57, p 
.0001).
bsolute and relative changes of NT-proBNP at
months and prognosis. Because 4-month NT-proBNP
as strongly associated with 2-year mortality, we assessed
hether changes in NT-proBNP between baseline and 4
onths would be a better predictor of outcome than a single
etermination. Three different methods, commonly used for
xpressing changes of concentrations, were compared in the
ame patient cohort. Figure 1A shows the relationship
etween quartiles of absolute change in NT-proBNP from
 Absolute changes
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Figure 1 Rate of Death by Quartiles of NT-proBNP Changes
Patients were divided according to quartiles of absolute (A) or percent relative
(B) changes of NT-proBNP over 4 months and rates of death at end point are
shown. Absolute changes were calculated as NT-proBNP4-month  NT-
proBNPbaseline. Relative changes were calculated as 100  ([NT-proBNP4-month 
NT-proBNPbaseline]/NT-proBNPbaseline). Number of events and total number of
patients for each quartile are shown above the bars. NT-proBNP  N-terminal
pro-brain natriuretic peptide.aseline to 4 months and subsequent death. Patients who
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Changes in NT-proBNP and Prognosis in HF September 16, 2008:997–1003ad the greatest absolute decrease (225 pg/ml) or
reatest absolute increase (213 pg/ml) in NT-proBNP
ver the 4-month period had the highest mortality (15.1%
nd 26.4%, respectively). Conversely, patients with inter-
ediate changes, between 225 and 213 pg/ml over the
months, had the lowest mortality (8.3% and 11.5%,
espectively). This is probably explained by the fact that
atients with the greatest absolute changes (either positive
r negative) had the highest baseline concentrations of
T-proBNP, compared with the 2 groups of patients with
ntermediate absolute changes (Fig. 1A). On the other
and, there was a progressive increase in the rate of all-cause
ortality (Fig. 1B) across quartiles of percent relative
hanges in NT-proBNP, from 9.2% in quartile 1 (reduction
31%) to 21.5% in quartile 4 (increase 33%, chi-square:
7.2, p  0.0001). To further test the association between
elative changes in NT-proBNP and outcome across the
hole range of NT-proBNP concentrations, we divided
atients into quartiles of baseline NT-proBNP concentra-
ion. The independent predictive value (from baseline con-
entration) of relative changes of NT-proBNP over 4
onths was estimated separately in each quartile with
ultivariate Cox models, including the variables associated
ith outcome in univariate analyses (Table 3). In these
odels, relative changes in NT-proBNP resulted as robust
nd significantly independent predictors of subsequent mor-
ality in all of the 4 quartiles of NT-proBNP concentration.
We compared the prognostic discrimination of a single
etermination of NT-proBNP (baseline or 4 months) versus
ontinuous changes, expressed as either relative (percent) or
bsolute changes, using time-dependent ROC analyses
Fig. 2). The single determination of NT-proBNP at 4
onths had the greatest prognostic accuracy (area under the
eceiver-operator characteristic curve [AUC]: 0.702, 95%
I: 0.669 to 0.735, p  0.0001 versus baseline NT-
roBNP) followed by baseline NT-proBNP levels (AUC:
.659, 95% CI: 0.624 to 0.690). Absolute and relative
percent) changes from baseline had overall lower prognos-
ic discrimination (AUC: 0.592, 95% CI: 0.549 to 0.634, p
0.026; and AUC: 0.602, 95% CI: 0.566 to 0.639, p 
.046, respectively).
ategorical changes of NT-proBNP. Kaplan-Meier sur-
ival curves for patients classified by categorical changes are
redictive Values of Relative (Percent) Changes in NT-proBNP Acro
Table 3 Predictive Values of Relative (Percent) Changes in NT-
Quartile of Baseline NT-proBNP
Concentration (n)
Baseline NT-proBNP Concentration (pg
Median (Minimum–Maximum)
Q1 (436) 199 (12–368)
Q2 (435) 571 (369–859)
Q3 (436) 1,210 (862–1,803)
Q4 (435) 2,982 (1,807–24,428)
atients were divided into quartiles of baseline concentration of NT-proBNP, and the independen
eparately in each quartile with multivariate Cox models, including the variables associated with o
%) of changes in NT-proBNP concentrations.
Abbreviations as in Tables 1 and 2.resented in Figure 3. The outcome of the 125 patients who
ad an NT-proBNP concentration above the ROC’s opti-
al prognostic cutoff value (1,078 pg/ml) at baseline but
elow this level at 4 months (high¡low) was comparable
ith those 904 patients who had levels below the cutoff
alue at the 2 time-points (low¡low, end point mortality
.2% vs. 8.9%). Likewise, outcome was similar in patients
ho maintained high levels of NT-proBNP (n  599,
ortality 25.7%) compared with those with worsened level
f NT-proBNP (low¡high, n  114, mortality 21.1%).
To evaluate the independent contribution of categorical
T-proBNP changes over time to outcome, a multivariate
ox regression analysis was performed in a model consid-
ring the 4 categories of NT-proBNP changes, baseline
T-proBNP, and the clinical variables associated with
utcome (Fig. 4). Patients who improved their NT-
roBNP at 4 months (high¡low) had a risk for all-cause
ortality (HR: 0.614, 95% CI: 0.290 to 1.302, p  0.2036)
hat was not significantly different from that of patients in
he reference category (low¡low). On the contrary, patients
uartiles of Baseline Concentrations
NP Across Quartiles of Baseline Concentrations
Number (Rate)
of Deaths
Predictive Value of Changes
in NT-proBNP
HR (95% CI) p Value
34 (7.8%) 1.143 (1.025–1.274) 0.0165
44 (10.1%) 1.390 (1.075–1.798) 0.0121
79 (18.1%) 1.615 (1.405–1.865) 0.0001
110 (25.3%) 1.352 (1.060–1.724) 0.0151
ctive value for risk of mortality of relative changes of NT-proBNP over 4 months was estimated
in univariate analyses. Hazard ratios and 95% CIs are presented for relative increments of 1 unit
All-cause mortality
0.0 0.2 0.4 0.6 0.8 1.0
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Figure 2 Time-Dependent Receiver-Operator
Characteristic Curves for All-Cause Mortality
Curves are based on univariate models of the prediction of risk at 24 months
with single determinations of NT-proBNP at baseline or 4 months or as percent-
age relative or absolute changes from baseline. Areas under the curves were
compared with the C-index. NT-proBNP  N-terminal pro-brain natriuretic
peptide.ss Q
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low¡high) had a significantly elevated risk of death (HR:
.699, 95% CI: 1.051 to 2.745, p  0.00305), close to that
f patients with elevated NT-proBNP at baseline and at 4
onths (high¡high, HR: 1.877, 95% CI: 1.180 to 2.986,
 0.0079) (Fig. 4). In this model, baseline concentration
f NT-proBNP (log-transformed) was not significantly
ssociated with mortality (HR: 1.174, 95% CI: 0.964 to
.430, p  0.1101).
iscussion
n the present study, which included a large and well-
ontrolled population of ambulatory patients with chronic,
table, and symptomatic HF, we found that: 1) changes over
months of NT-proBNP concentrations in patients with
hronic and stable HF are associated with long-term out-
ome; 2) the relationship between outcome and changes in
T-proBNP depends largely on the way these changes are
xpressed (i.e., as absolute differences of concentrations or as
elative changes with respect to a baseline concentration);
nd 3) a single determination of NT-proBNP shows a
igher prognostic discrimination during the course of a
trict clinical monitoring period than continuous changes of
oncentrations, expressed either as absolute or relative
hanges, whereas categorical changes of NT-proBNP con-
entration across a threshold value predict outcome inde-
endently of a single determination. The size and represen-
ativeness of the sample studied allows epidemiological
ranslation of several fragmented observations from smaller
Figure 3 Kaplan-Meier Curves for All-Cause Mortality in the 4 C
Patients were divided into 4 categories according to NT-proBNP concentrations at
curves. Low¡low (patients with NT-proBNP below threshold at baseline and 4 mon
line and 4 months, n  599), high¡low (NT-proBNP above to below threshold, n 
chi-square  96.5, p  0.0001. NT-proBNP  N-terminal pro-brain natriuretic peptudies.Since their initial discovery (14,15), there has been
onsiderable evidence showing that a single determination
f a natriuretic peptide (BNP or NT-proBNP) at any time
uring the progression of the disease has prognostic value in
atients with chronic HF, even on top of robust clinical
ariables. The importance of changes over time in natri-
retic peptide concentrations as a prognostic marker in
atients with chronic HF has previously been investigated
Figure 4 Risk of Death by Baseline NT-proBNP
and Categories of Changes Over 4 Months
Patients were divided into 4 categories according to NT-proBNP concentration
at baseline and 4 months relative to a threshold of 1,078 pg/ml. A multivari-
ate Cox proportional hazards model was used to compare the risk of death
among the 4 categories of patients and by baseline NT-proBNP concentration
(log-transformed) using the low¡low group as a referent. The model was
adjusted for clinical variables with statistically significant association to out-
come (age, body mass index, serum creatinine at baseline, ischemic etiology
of heart failure, New York Heart Association functional class, left ventricular
ejection fraction and diameter, and prescription of digoxin and diuretics). Data
are presented as hazard ratio (HR) and 95% confidence interval (CI). NT-proBNP
ories of Patients
e and 4 months relative to a threshold (1,078 pg/ml) determined by ROC
 904 patients), high¡high (patients with NT-proBNP above threshold at base-
), and low¡high (NT-proBNP below to above threshold, n  114). Log-rank test,
OC  receiver-operator characteristic. N-terminal pro-brain natriuretic peptide.ateg
baselin
ths, n
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Changes in NT-proBNP and Prognosis in HF September 16, 2008:997–10033,6,8,16). In a recent study, a cohort of 190 ambulatory
atients with chronic HF (NYHA functional class III to IV)
as prospectively enrolled, and BNP and cardiac troponin T
cTnT) were measured at baseline and every 3 months for 2
ears (7). Elevation of BNP or cTnT detected at any time
uring clinical follow-up was highly associated with an
ncreased risk for adverse events (death, cardiac transplan-
ation, or hospitalization). Interestingly, whereas a new
levation of BNP from normal to above normal concentra-
ion was associated with an incremental risk, once elevated
t any time, subsequent changes in BNP (increase or
ecrease) did not translate into a modulation of risk cate-
ory, in contrast to what was observed for cTnT (7).
As observed previously with BNP in the Val-HeFT trial,
e confirm here that changes over time in the concentration
f the inactive fragment NT-proBNP are similarly associ-
ted with outcome in patients with chronic HF when
xpressed either as continuous absolute or relative changes
8) or as categorical changes across a threshold value (3).
he relationship between outcome and continuous changes
f BNP, as well as NT-proBNP, depends largely on
hether these changes are expressed as absolute differences
concentration at timei1  concentration at timei] or
elative differences (absolute changes normalized by initial
evel). It is intuitive that the same absolute decrease in a
atient with a very high initial concentration is unlikely to
ave the same prognostic significance than in a patient with
low initial NT-proBNP concentration. Normalizing the
bsolute differences by the initial concentration yielded an
lmost linear relationship between quartiles of BNP (8) or
T-proBNP and mortality (Fig. 1B).
Changes across pre-defined threshold values have been
lternatively proposed. Definition of the threshold level may
e on a statistical basis (median concentrations of the
opulation studied, ROC-derived optimal cutoff value) or
linical basis (upper limit of the reference value in healthy
ndividuals, diagnostic cutoff values). In a substudy of the
OMET (Carvedilol Or Metoprolol European Trial)
tudy, 309 patients with chronic HF (NYHA functional
lass II to IV, LVEF 0.35) had NT-proBNP measured at
andomization and at a follow-up time varying between 12
nd 36 months (17). A threshold of 400 pg/ml (upper
eference value in elderly healthy women) was chosen to
ivide patients according to baseline NT-proBNP level. In
his study, it was shown that among patients with a baseline
oncentration of NT-proBNP 400 pg/ml, subsequent
ortality was significantly lower in those who reached a
evel below this threshold at follow-up (risk ratio: 0.35, 95%
I: 0.15 to 0.82, p  0.017) (17). We have previously
hown that stratification of patients into 4 categories ac-
ording to BNP levels at 2 time points with respect to a
edian concentration provided prognostic information in
atients with chronic HF beyond that of a single determi-
ation (3). The same approach and conclusion can be found
n a prospective study that enrolled 133 patients with severe
F referred for consideration of cardiac transplantation t18). In the present study, the threshold level was derived
rom an ROC analysis and the calculated optimal cutoff
oncentration (1,078 pg/ml) is in fact close to the median
oncentration at study entry (861 pg/ml), so that our
ndings should be relatively independent of the way the
hreshold was calculated. We showed that most patients in
he placebo arm had stable low (51.9%) or high (34.4%)
evels of NT-proBNP over 4 months of follow-up, in
greement with the definition of the population studied.
evertheless, changes of category were associated with
arked modification of the prognosis. In other words,
imilar concentrations of NT-proBNP at a given time can
ave profoundly different prognostic values, depending on
he subsequent trend in these patients. For instance, pa-
ients with an initial NT-proBNP concentration below the
hreshold level have, on average, markedly divergent out-
omes depending on whether they maintain (mortality rate
.9%) or worsen their level of NT-proBNP (21.1%). Con-
ersely, mortality rate is drastically different in patients with
table high levels of NT-proBNP (25.7%) compared with
hose with decreasing NT-proBNP (7.2%). Further, the
rognostic value of categorical changes in NT-proBNP was
ndependent of and incremental to a single determination of
T-proBNP in multivariate models that also included
obust clinical risk factors. Finally, the categorical changes
eem to be more easily understood than continuous absolute
r relative changes and may be transferred more readily into
linical practice. Although not formally tested in the present
tudy, major differences in the prognostic value of repeated
eterminations of BNP and NT-proBNP in chronic HF are
nlikely, as already reported in patients presenting with
hest pain (19).
To the best of our knowledge, this is the first evaluation
nd head-to-head comparison of the prognostic discrimi-
ation of different strategies for risk stratification using a
atriuretic peptide in a large population of patients with
table and chronic HF. In a different setting, acute HF,
T-proBNP was serially determined in 116 patients at the
ime of initiation of intravenous therapy (baseline) and at
ifferent intervals until discharge from the hospital (20). It
as shown, comparing the AUC of time-dependent ROC
urves, that single absolute concentrations of NT-proBNP
in particular at discharge) had the highest prognostic
ccuracy, ahead of absolute or relative changes from base-
ine. With different statistical approaches, other studies also
oncluded the superiority of single-measurement over ab-
olute or relative changes in advanced (18) or decompen-
ated HF (21). Our data confirm and extend these obser-
ations to patients with chronic and stable HF. They also
upport the hypothesis that serial determinations of natri-
retic peptide (BNP or NT-proBNP) concentration and
lassification into few categories of changes according to
hreshold levels may be a superior strategy for risk stratifi-
ation of patients with chronic and stable HF, and thus offer
n aid in monitoring these patients or actively guiding
itration of treatment (22,23).
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September 16, 2008:997–1003 Changes in NT-proBNP and Prognosis in HFtudy limitations. Natriuretic peptide elevation may re-
ect the progression of the underlying disease that nega-
ively influences prognosis, but also superimposed volume
xpansion and worsening of symptoms, which may not have
he same impact on outcomes. A decrease in natriuretic
eptide may reflect the effect of therapy, such as more
iuretic, without any improvement in outcomes or the
esolution of an initial elevation caused by volume overload,
lthough outcome is dependent on underlying severity of
yocardial disease. All of these possibilities should be borne
n mind when interpreting changes in natriuretic peptide
oncentrations over time. However, the lack of a reliable
stimate of volume overload makes it difficult to fully
nterpret the changes observed. Finally, ROC curves and
-statistics, although widely used, may not be the optimal
ool for assessing the impact of a new marker in risk
rediction models containing standard risk factors (24,25).
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